Author: Sheehan, Stephanie A.; Hamilton, Kelly L.; Retzbach, Edward P.; Balachandran, Premalatha; Krishnan, Harini; Leone, Paola; Lopez-Gonzalez, Moises; Suryavanshi, Shraddha; Kumar, Pradeep; Russo, Riccardo; Goldberg, Gary S.
Title: Evidence that Maackia amurensis seed lectin (MASL) exerts pleiotropic actions on oral squamous cells with potential to inhibit SARS-CoV-2 infection and COVID-19 disease progression Cord-id: kpvne9ys Document date: 2021_6_1
ID: kpvne9ys
Snippet: COVID-19 was declared an international public health emergency in January, and a pandemic in March of 2020. There are over 125 million confirmed COVID-19 cases that have caused over 27 million deaths worldwide as of March 2021. COVID-19 is caused by the SARS-CoV-2 virus. SARS-CoV-2 presents a surface “spike†protein that binds to the ACE2 receptor to infect host cells. In addition to the respiratory tract, SARS-Cov-2 can also infect cells of the oral mucosa, which also express the ACE2 recep
Document: COVID-19 was declared an international public health emergency in January, and a pandemic in March of 2020. There are over 125 million confirmed COVID-19 cases that have caused over 27 million deaths worldwide as of March 2021. COVID-19 is caused by the SARS-CoV-2 virus. SARS-CoV-2 presents a surface “spike†protein that binds to the ACE2 receptor to infect host cells. In addition to the respiratory tract, SARS-Cov-2 can also infect cells of the oral mucosa, which also express the ACE2 receptor. The spike and ACE2 proteins are highly glycosylated with sialic acid modifications that direct viral-host interactions and infection. Maackia amurensis seed lectin (MASL) has a strong affinity for sialic acid modified proteins and can be used as an antiviral agent. Here, we report that MASL targets the ACE2 receptor, decreases ACE2 expression and glycosylation, suppresses binding of the SARS-CoV-2 spike protein, and decreases expression of inflammatory mediators by oral epithelial cells that cause ARDS in COVID-19 patients. In addition, we report that MASL also inhibits SARS-CoV-2 infection of kidney epithelial cells in culture. This work identifies MASL as an agent with potential to inhibit SARS-CoV-2 infection and COVID-19 related inflammatory syndromes.
Search related documents:
Co phrase search for related documents- acid residue and luciferase reporter construct: 1
- acid residue and lysis buffer: 1
- actin expression and acute ards respiratory distress syndrome: 1
- actin expression and luciferase reporter: 1
- actin expression and lung inflammation: 1
- actin expression and lysis buffer: 1
- activity signal and acute ards respiratory distress syndrome: 1
- activity signal and live cell imaging: 1, 2
- activity signal and luciferase reporter: 1, 2
- activity signal and lysis buffer: 1
- acute ards respiratory distress syndrome and adolescent child: 1
- acute ards respiratory distress syndrome and live cell imaging: 1
- acute ards respiratory distress syndrome and luciferase reporter: 1, 2, 3, 4
- acute ards respiratory distress syndrome and lung epithelial cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute ards respiratory distress syndrome and lung epithelium: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- acute ards respiratory distress syndrome and lung inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- live cell imaging and luciferase reporter: 1
- live cell imaging and lung epithelial cell: 1
- luciferase reporter and lung epithelial cell: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date